Tom 10, Nr 1 (2018)
Artykuły
Opublikowany online: 2018-08-13

dostęp otwarty

Wyświetlenia strony 1756
Wyświetlenia/pobrania artykułu 7110
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Przewlekłe zaparcia — niedoceniany problem kliniczny

Jarosław Daniluk
Gastroenterologia Kliniczna 2018;10(1):1-13.

Streszczenie

Przewlekłe zaparcia należą do najczęstszych schorzeń układu pokarmowego, na które choruje około 14% populacji na świecie. Do typowych objawów należą zmniejszona liczba wypróżnień (< 3/tydzień), wysiłek podczas defekacji, uczucie niepełnego wypróżnienia, oddawanie twardego stolca. Przewlekłe zaparcia mogą być spowodowane Między innymi wydłużonym czasem pasażu jelitowego stolca, zaburzeniami defekacji lub mieć charakter wtórny do innych chorób. Patofizjologia przewlekłych zaparć jest wieloczynnikowa i nie została do końca wyjaśniona. Diagnoza powinna być ustalona na podstawie standardowo przyjętych kryteriów. Zaawansowane badania diagnostyczne są zalecane jedynie w przypadku nieskuteczności terapii początkowej. Większość pacjentów z przewlekłymi zaparciami powinna być leczona przez lekarza podstawowej opieki zdrowotnej. Terapia obejmuje identyfikację i eliminację wtórnych przyczyn zaparć, zmianę stylu życia (zwiększone spożycie płynów i błonnika, prawidłowa aktywność fizyczna). Leczeniem pierwszego wyboru jest podawanie osmotycznych i stymulujących środków przeczyszczających. Leki prokinetyczne i pobudzające wydzielanie, jak również leczenie chirurgiczne powinny być zarezerwowane dla wyselekcjonowanej grupy pacjentów niereagujących na standardowe leczenie.

Artykuł dostępny w formacie PDF

Pokaż PDF Pobierz plik PDF

Referencje

  1. Peery AF, Crockett SD, Barritt AS, et al. Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States. Gastroenterology. 2015; 149(7): 1731–1741.e3.
  2. Ziółkowski B, Pacholec A, Kudlicka M, et al. Prevalence of abdominal symptoms in the Polish population. Gastroenterology Review. 2012; 1: 20–25.
  3. Pare P, Ferrazzi S, Thompson WG, et al. An epidemiological survey of constipation in canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol. 2001; 96(11): 3130–3137.
  4. Stewart SL, Wike JM, Kato I, et al. A population-based study of colorectal cancer histology in the United States, 1998-2001. Cancer. 2006; 107(5 Suppl): 1128–1141.
  5. Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol. 2011; 106(9): 1582–91; quiz 1581, 1592.
  6. Stewart WF, Liberman JN, Sandler RS, et al. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. Am J Gastroenterol. 1999; 94(12): 3530–3540.
  7. Sandler RS, Jordan MC, Shelton BJ. Demographic and dietary determinants of constipation in the US population. Am J Public Health. 1990; 80(2): 185–189.
  8. Levy EI, Lemmens R, Vandenplas Y, et al. Functional constipation in children: challenges and solutions. Pediatric Health Med Ther. 2017; 8: 19–27.
  9. Berterame S, Erthal J, Thomas J, et al. Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study. Lancet. 2016; 387(10028): 1644–1656.
  10. Wald A. Constipation: Advances in Diagnosis and Treatment. JAMA. 2016; 315(2): 185–191.
  11. Chey WD, Webster L, Sostek M, et al. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014; 370(25): 2387–2396.
  12. Bell T, Annunziata K, Leslie JB. Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness Survey. J Opioid Manag. 2009; 5(3): 137–144.
  13. Bharucha AE, Dorn SD, Lembo A, et al. American Gastroenterological Association. American Gastroenterological Association medical position statement on constipation. Gastroenterology. 2013; 144(1): 211–217.
  14. Surrenti E, Rath DM, Pemberton JH, et al. Audit of constipation in a tertiary referral gastroenterology practice. Am J Gastroenterol. 1995; 90(9): 1471–1475.
  15. Lyford GL, He CL, Soffer E, et al. Decreased interstitial cell of cajal volume in patients with slow-transit constipation. Gastroenterology. 2000; 118(1): 14–21.
  16. Dinning PG, Wiklendt L, Maslen L, et al. Colonic motor abnormalities in slow transit constipation defined by high resolution, fibre-optic manometry. Neurogastroenterol Motil. 2015; 27(3): 379–388.
  17. Saad RJ, Rao SSC, Koch KL, et al. Do stool form and frequency correlate with whole-gut and colonic transit? Results from a multicenter study in constipated individuals and healthy controls. Am J Gastroenterol. 2010; 105(2): 403–411.
  18. Soh JS, Lee HJ, Jung KW, et al. The diagnostic value of a digital rectal examination compared with high-resolution anorectal manometry in patients with chronic constipation and fecal incontinence. Am J Gastroenterol. 2015; 110(8): 1197–1204.
  19. Rao SSC, Singh S. Clinical utility of colonic and anorectal manometry in chronic constipation. J Clin Gastroenterol. 2010; 44(9): 597–609.
  20. Minguez M, Herreros B, Sanchiz V, et al. Predictive value of the balloon expulsion test for excluding the diagnosis of pelvic floor dyssynergia in constipation. Gastroenterology. 2004; 126(1): 57–62.
  21. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther. 2007; 25(5): 599–608.
  22. De Schryver AM, Keulemans YC, Peters HP, et al. Effects of regular physical activity on defecation pattern in middle-aged patients complaining of chronic constipation. Scand J Gastroenterol. 2005; 40(4): 422–429.
  23. Villoria A, Serra J, Azpiroz F, et al. Physical activity and intestinal gas clearance in patients with bloating. Am J Gastroenterol. 2006; 101(11): 2552–2557.
  24. Markland AD, Palsson O, Goode PS, et al. Association of low dietary intake of fiber and liquids with constipation: evidence from the National Health and Nutrition Examination Survey. Am J Gastroenterol. 2013; 108(5): 796–803.
  25. Ashraf W, Park F, Lof J, et al. Effects of psyllium therapy on stool characteristics, colon transit and anorectal function in chronic idiopathic constipation. Aliment Pharmacol Ther. 1995; 9(6): 639–647.
  26. Ford AC, Moayyedi P, Lacy BE, et al. Task Force on the Management of Functional Bowel Disorders. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014; 109 Suppl 1: S2–26; quiz S27.
  27. Anti M, Pignataro G, Armuzzi A, et al. Water supplementation enhances the effect of high-fiber diet on stool frequency and laxative consumption in adult patients with functional constipation. Hepatogastroenterology. 1998; 45(21): 727–732.
  28. Dipalma JA, Cleveland MVb, McGowan J, et al. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol. 2007; 102(7): 1436–1441.
  29. Lee-Robichaud H, Thomas K, Morgan J, et al. Lactulose versus Polyethylene Glycol for Chronic Constipation. Cochrane Database Syst Rev. 2010(7): CD007570.
  30. Rendeli C, Ausili E, Tabacco F, et al. Polyethylene glycol 4000 vs. lactulose for the treatment of neurogenic constipation in myelomeningocele children: a randomized-controlled clinical trial. Aliment Pharmacol Ther. 2006; 23(8): 1259–1265.
  31. Gattuso JM, Kamm MA. Adverse effects of drugs used in the management of constipation and diarrhoea. Drug Saf. 1994; 10(1): 47–65.
  32. Chassagne P, Ducrotte P, Garnier P, et al. Tolerance and Long-Term Efficacy of Polyethylene Glycol 4000 (Forlax®) Compared to Lactulose in Elderly Patients with Chronic Constipation. J Nutr Health Aging. 2017; 21(4): 429–439.
  33. Kamm MA, Mueller-Lissner S, Wald A, et al. Oral bisacodyl is effective and well-tolerated in patients with chronic constipation. Am J Gastroenterol. 2011; 105(9): 577–583.
  34. Mueller-Lissner S, Kamm MA, Wald A, et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation. Am J Gastroenterol. 2010; 105(4): 897–903.
  35. Camilleri M, Piessevaux H, Yiannakou Y, et al. Efficacy and safety of prucalopride in chronic constipation: an integrated analysis of six randomized, controlled clinical trials. Dig Dis Sci. 2016; 61(8): 2357–2372.
  36. Hayat U, Dugum M, Garg S. Chronic constipation: Update on management. Cleve Clin J Med. 2017; 84(5): 397–408.
  37. Lembo AJ, Kurtz CB, Macdougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology. 2010; 138(3): 886–95.e1.
  38. Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med. 2011; 365(6): 527–536.
  39. Johanson JF, Morton D, Geenen J, et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol. 2008; 103(1): 170–177.
  40. Lacy BE, Levy LC. Lubiprostone: a novel treatment for chronic constipation. Clin Interv Aging. 2008; 3(2): 357–364.
  41. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012; 107(11): 1702–1712.
  42. Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut. 2011; 60(2): 209–218.
  43. Chiarioni G, Salandini L, Whitehead WE. Biofeedback benefits only patients with outlet dysfunction, not patients with isolated slow transit constipation. Gastroenterology. 2005; 129(1): 86–97.
  44. Rao SSC, Valestin J, Brown CK, et al. Long-term efficacy of biofeedback therapy for dyssynergic defecation: randomized controlled trial. Am J Gastroenterol. 2010; 105(4): 890–896.
  45. Pemberton JH, Rath DM, Ilstrup DM. Evaluation and Surgical Treatment of Severe Chronic Constipation. Annals of Surgery. 1991; 214(4): 403–413.
  46. Arebi N, Kalli T, Howson W, et al. Systematic review of abdominal surgery for chronic idiopathic constipation. Colorectal Dis. 2011; 13(12): 1335–1343.
  47. Dudekula A, Huftless S, Bielefeldt K. Colectomy for constipation: time trends and impact based on the US Nationwide Inpatient Sample, 1998-2011. Aliment Pharmacol Ther. 2015; 42(11-12): 1281–1293.
  48. Jayne DG, Schwandner O, Stuto A. Stapled transanal rectal resection for obstructed defecation syndrome: one-year results of the European STARR Registry. Dis Colon Rectum. 2009; 52(7): 1205–12; discussion 1212.
  49. Madbouly KM, Abbas KS, Hussein AM. Disappointing long-term outcomes after stapled transanal rectal resection for obstructed defecation. World J Surg. 2010; 34(9): 2191–2196.
  50. Kamm MA, Dudding TC, Melenhorst J, et al. Sacral nerve stimulation for intractable constipation. Gut. 2010; 59(3): 333–340.
  51. Worsøe J, Christensen P, Krogh K, et al. Long-term results of antegrade colonic enema in adult patients: assessment of functional results. Dis Colon Rectum. 2008; 51(10): 1523–1528.